Exhibit 99.1

SXC HEALTH SOLUTIONS ANNOUNCES RECORD

THIRD QUARTER FINANCIAL RESULTS

- Following strong quarterly results, SXC increases guidance for fiscal 2009 -

Lisle, Illinois, November 5, 2009 - SXC Health Solutions Corp. (“SXC” or the “Company”) (NASDAQ: SXCI, TSX: SXC), announces its financial results for the three- and nine-month periods ended September 30, 2009.  Financial references are in U.S. dollars unless otherwise indicated.

Q3 2009 Highlights

• Revenue was $383.5 million compared to $318.1 million in Q3 fiscal 2008

• Gross profit was $47.7 million compared to $34.9 million in Q3 fiscal 2008

• Adjusted EBITDA¹ was $24.3 million compared to $11.9 million in Q3 fiscal 2008

• GAAP net income increased to $11.2 million, or $0.43 per share (fully-diluted), compared to $3.5 million, or $0.15 per share (fully-diluted), in Q3 fiscal 2008

• Non-GAAP adjusted earnings per share¹ (diluted), which excludes the NMHC transaction-related amortization, was $0.47 compared to $0.24 in Q3 fiscal 2008

• Cash from operations was $17.9 million compared to $3.3 million in Q3 fiscal 2008

• Adjusted prescription claim volume1 for the PBM segment was 9.9 million compared to 8.9 million in Q3 fiscal 2008

• Gross margin per adjusted prescription for the PBM segment was $3.67 compared to $2.77 in Q3 fiscal 2008

• Mail order penetration increased to 9.5% compared to 8% in Q3 fiscal 2008

• Transaction processing volume for the HCIT segment was 92.0 million in Q3 fiscal 2009 compared to 103.3 million in Q3 fiscal 2008

• Awarded a contract with the Ohio Bureau of Workers' Compensation, the largest workers compensation organization in the U.S.

• Awarded a PBM services contract with Presbyterian Health Plan valued at $150 million annually

• Renewed a multi-year PBM contract with the Employer-Union Health Benefits Trust Fund of Hawaii

• Entered into a strategic relationship with Allscripts Misys to enhance the e-prescribing options available to SXC’s clients

• Completed a public offering of 5,175,000 common shares at a price of $41.50 per share for net proceeds of approximately $204.1 million

• Subsequent to quarter-end, announced a PBM contract with Spectral Solutions valued at $50 million annually

“Solid execution on our growth strategies combined with sound fundamentals in our markets led to another strong quarter and an increase to our key guidance targets,” said Mark Thierer, President and CEO of SXC. “In addition to new customer wins, we are driving both top-line and bottom-line growth by increasing the mail-order penetration in our customer base and converting a number of Health Care IT clients to a broader platform of our PBM services. With future growth in mind, we completed a successful $204 million financing in the quarter that was oversubscribed by investors. The proceeds provide us with the resources to explore acquisition opportunities and to pursue the growing sales pipeline with prospective and existing clients.”

1

Financial Review

Revenue and gross profit segmented by PBM and HCIT was as follows:

SXC evaluates segment performance based on revenue and gross profit. A reconciliation of the Company’s business segments to the consolidated financial statements for the three- and nine-month periods ended September 30, 2009 and 2008 is as follows:

Three months ended September 30, (unaudited, in thousands)

	PBM						HCIT						Consolidated
		Q3 2009			Q3 2008			Q3 2009			Q3 2008			Q3 2009			Q3 2008
Revenue	$	357,473		$	297,178		$	26,056		$	20,923		$	383,529		$	318,101
Gross profit	$	36,239		$	24,524		$	11,441		$	10,362		$	47,680		$	34,886
Gross profit %		10.1	%		8.3	%		43.9	%		49.5	%		12.4	%		11.0	%

 Nine months ended September 30, (unaudited, in thousands)²

	PBM						HCIT						Consolidated
	YTD 09			YTD 08			YTD 09			YTD 08			YTD 09			YTD 08
Revenue	$	919,158		$	502,038		$	76,160		$	68,135		$	995,318		$	570,173
Gross profit	$	99,550		$	41,338		$	34,526		$	36,668		$	134,076		$	78,206
Gross profit %		10.8	%		8.2	%		45.3	%		53.8	%		13.5	%		13.7	%

PBM revenue was $357.5 million for Q3 2009, compared to $297.2 million for Q3 2008. PBM revenue for the year-to-date (“YTD”) period was $919.2 million, compared to $502.0 million in the prior year.

Q3 2009 HCIT revenue was $26.1 million, which included approximately $1.5 million of performance awards for achieving certain predetermined savings commitments and service level guarantees, compared to $20.9 million in the same period in 2008.  Recurring revenue consisted of transaction processing revenue of $16.5 million, compared to $11.6 million in Q3 2008 and maintenance revenue of $4.7 million, compared to $4.0 million in Q3 2008. Recurring revenue accounted for 81% of HCIT revenue in Q3 2009, compared to 75% in Q3 2008. Q3 2009 non-recurring revenue consisted of professional service revenue of $3.2 million, compared to $3.8 million in Q3 2008, and system sales revenue of $1.7 million, compared to $1.5 million in Q3 2008.

For the YTD period, HCIT revenue increased to $76.2 million, compared to $68.1 million in the prior year period. Transaction processing revenue for the YTD period was $45.9 million, compared to $38.2 million in the prior year period. Maintenance revenue for the YTD period was $13.7 million, compared to $12.3 million in the prior year period. Recurring revenue in the YTD period accounted for 78% of HCIT revenue compared to 74% in the prior year period. Professional services revenue for the YTD period was $10.6 million, compared to $10.7 million in the prior year period.  System sales revenue for the YTD period was $6.0 million, compared to $6.9 million in the prior year period.

Product Development Costs

Product development costs for Q3 2009 were $2.8 million, compared to $2.5 million in Q3 2008.  Product development costs for the YTD period were $9.0 million, compared to $7.4 million in the prior year period. Product development remains a key priority for SXC as the Company seeks to develop enhancements to existing products and the launch of new offerings.

2

Selling, General and Administration (“SG&A”) Costs

SG&A costs for Q3 2009 were $22.2 million, compared to $21.9 million in Q3 2008.SG&A for the YTD period was $64.9 million, compared to $47.3 million in the prior year period. On a quarter-over-quarter basis, the Company has added a significant level of new business while keeping SG&A costs relatively flat. The change in the YTD period is largely attributable to increased operating expenses due to the acquisition of NMHC.

Adjusted EBITDA¹

Q3 2009 adjusted EBITDA was $24.3 million, compared to $11.9 million in Q3 2008. Adjusted EBITDA for the YTD period was $64.3 million, compared to $27.8 million in the prior year period. The year-over-year growth in adjusted EBITDA was due primarily to the addition of the NMHC business, cost and revenue synergies generated from the acquisition, new contract wins and improved purchasing efficiencies on prescription drugs.

Income Taxes

The Company recognized income tax expense of $6.8 million in Q3 2009, compared to an income tax expense of $1.3 million in Q3 2008. Income tax expense for the YTD period was $14.9 million, representing an effective tax rate of 32.5%, compared to an income tax expense of $3.5 million in the prior year period, representing an effective tax rate of 25.3%. The effective income tax rate increased year-over-year primarily due to greater pre-tax income that has resulted from the growth in the business.

Net Income

The Company reported Q3 2009 net income of $11.2 million, or $0.43 per share (fully-diluted), which included $1.7 million of intangible amortization related to the purchase of NMHC, compared to $3.5 million, or $0.15 per share (fully-diluted), which included $3.1 million of NMHC intangible amortization, in Q3 2008. Net income for the YTD period was $30.9 million, or $1.22 per share (fully-diluted), which also included $5.9 million of NMHC intangible amortization, compared to net income in the prior year period of $10.2 million, or $0.44 per share (fully-diluted), which included $5.1 million of NMHC intangible amortization.

Cash from Operations

SXC continues to generate strong cash from operations. For Q3 2009, the Company generated $17.9 million of cash through its operations, compared to $3.3 million during Q3 2008. The Company’s quarterly cash flows can be impacted by the timing of pharmacy deposits and rebate payments it receives for certain customers. For the YTD period, SXC generated cash from operations of $49.6 million, compared to $20.6 million in the prior year period.

At September 30, 2009 and December 31, 2008, SXC had cash and cash equivalents totalling $319.5 million and $67.7 million, respectively. On September 23, 2009, SXC completed a public offering of 5,175,000 of its common shares, including 675,000 shares sold pursuant to the exercise of the underwriters' over-allotment option, for net proceeds to the Company of approximately $204.1 million.

3

2009 Financial Guidance

With today’s announcement, SXC is revising certain of its 2009 financial targets for:

• Revenue of $1.375-$1.425 billion versus prior estimate of $1.35-$1.4 billion

• Gross profit of $180-$182 million versus prior estimate of $166-$171 million

• Fully-diluted GAAP EPS (including all transaction-related amortization) of $1.57-$1.62 versus prior estimate of $1.42-$1.50

• Adjusted EBITDA of $87-$89 million versus prior estimate of $78-$81 million

• Fully-diluted Non-GAAP adjusted earnings per share¹ (excluding the NMHC transaction-related amortization) of $1.76-$1.81 versus prior estimate of $1.62-$1.70

Notice of Conference Call

SXC will host a conference call on Thursday, November 5, 2009 at 8:30 a.m. ET to discuss its financial results.  Mark Thierer, President and CEO, and Jeff Park, EVP and CFO will co-chair the call. All interested parties can join the call by dialing 1-866-250-4877or 416-644-3422. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until Thursday, November 12, 2009 at midnight. To access the archived conference call, please dial 1-877-289-8525 or 416-640-1917 and enter the reservation code 4169797 followed by the number sign.

A live audio webcast of the conference call will be available www.sxc.com and www.newswire.ca. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. An archived replay of the webcast will be available for 365 days.

1Non-GAAP Financial Measures

SXC reports its financial results in accordance with generally accepted accounting principles in the United States (“GAAP”). SXC’s management also evaluates and makes operating decisions using various other measures. Two such measures are adjusted earnings per share and adjusted EBITDA, which are non-GAAP financial measures. SXC’s management believes that these measures provide useful supplemental information regarding the performance of SXC’s business operations.

Adjusted earnings per share is a non-GAAP measure which takes earnings per share and adds back the impact of amortization expense related to the acquisition of NMHC, net of tax.  Acquisition-related amortization expense is a non-cash expense arising from the acquisition of intangible assets in connection with the acquisition. SXC excludes acquisition-related amortization expense from non-GAAP adjusted earnings per share because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of SXC business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contribute to revenue in the period presented as well as future periods and should also note that such expense will recur in future periods. The 2009 guidance of adjusted earnings per share was computed by taking the Company's GAAP earnings per share guidance and adding back the expected impact of acquisition-related amortization expense, net of tax.

4

Adjusted EBITDA is a non-GAAP measure that management believes is a useful supplemental measure of operating performance prior to net interest income (expense), income taxes, depreciation, amortization and stock-based compensation.  Management believes it is useful to exclude depreciation, amortization and net interest income (expense) as these are essentially fixed amounts that cannot be influenced by management in the short term. In addition, management believes it is useful to exclude stock-based compensation as this is not a cash expense.

Adjusted prescription volume equals SXC’s Mail Service prescriptions multiplied by three, plus its retail and specialty prescriptions. The Mail Service prescriptions are multiplied by three to adjust for the fact that they typically include approximately three times the amount of product days supplied compared with retail prescriptions.

Management believes that adjusted earnings per share, adjusted EBITDA and adjusted prescription volume provide useful supplemental information to management and investors regarding the performance of the Company’s business operations and facilitate comparisons to its historical operating results. Management also uses this information internally for forecasting and budgeting as it believes that the measures are indicative of the Company’s core operating results. Note however, that these items are performance measures only, and do not provide any measure of the Company’s cash flow or liquidity. Non-GAAP financial measures should not be considered as a substitute for measures of financial performance in accordance with GAAP, and investors and potential investors are encouraged to review the reconciliation of adjusted earnings per share and adjusted EBITDA.

Adjusted earnings per share and adjusted EBITDA do not have standardized meanings prescribed by GAAP. The Company's method of calculating these items may differ from the methods used by other companies and, accordingly, it may not be comparable to similarly titled measures used by other companies. Reconciliation of adjusted EBITDA to net income and adjusted net income to net income is shown below:

5

	For the three months ended						For the nine months ended
	September 30,						September 30,
	2009			2008			2009			2008
	(unaudited) (in thousands)
Adjusted EBITDA	$	24,310		$	11,886		$	64,298		$	27,795
Amortization of Intangible Assets		(2,238	)		(3,449	)		(7,478	)		(6,277	)
Depreciation of Property & Equipment		(2,037	)		(1,669	)		(5,981	)		(4,715	)
Stock-Based Compensation		(1,046	)		(902	)		(2,476	)		(3,006	)
Other Income (Expense)		20			50			62			15
Interest Income (Expense), Net		(987	)		(1,101	)		(2,676	)		(198	)
Income Tax (Expense)		(6,813	)		(1,276	)		(14,881	)		(3,451	)
Net Income	$	11,209		$	3,539		$	30,868		$	10,163

Non-GAAP Adjusted Earnings Per Share	For the 3 months ended Sept 30, 2009		For the 3 months ended Sept 30, 2008
(unaudited) (in thousands, except per share data)
Net Income	$	11,209	$	3,539
Amortization of NMHC Intangibles (Net of Taxes)		1,027		2,244
Adjusted Net-Income	$	12,236		5,783
Adjusted EPS (diluted)	$	0.47	$	0.24

2On April 30, 2008, SXC closed the acquisition of NMHC. As a result, SXC has introduced some new segmentation and presentation of its financial results. Revenue is now segmented into two groups: Pharmacy Benefits Management (“PBM”) which includes informedRx as well as mail-order and specialty pharmacies, and Healthcare Information Technology (“HCIT”). SXC records PBM revenue from NMHC exclusively on a gross basis which equates to the prescription price paid by consumers plus an administrative fee. The HCIT business records revenue only on the basis of the administrative fee; drug ingredient cost is not included in revenues or cost of claims.

The net effect is that SXC’s year-over-year revenues have increased dramatically while gross profit margin and adjusted EBITDA have increased in absolute dollar terms, but have declined as a percentage of total sales. These changes do not affect profitability on an absolute dollar or per share basis.

6

About SXC Health Solutions Corp.

SXC Health Solutions Corp. is a leading provider of pharmacy benefit management (“PBM”) services and Healthcare Information Technology (“HCIT”) solutions to the healthcare benefits management industry. As the industry’s “Technology-Enabled PBM”™, SXC’s product offerings and solutions combine a wide range of advanced PBM services, software applications, application service provider processing services, and professional services to help healthcare organizations reduce the cost of prescription drugs and deliver better healthcare to their members. SXC serves many of the largest organizations in the pharmaceutical supply chain, such as health plans; employers; Federal, provincial, and state governments; institutional pharmacies; pharmacy benefit managers; and retail pharmacy chains. SXC is headquartered in Lisle, Illinois with multiple locations in North America. Learn more at www.sxc.com.

Forward-Looking Statements

Certain statements included herein, including those that express management's expectations or estimates of our future performance, constitute "forward-looking statements" within the meaning of applicable securities laws.Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies.We caution that such forward-looking statements involve known and unknown risks, uncertainties and other risks that may cause our actual financial results, performance, or achievements to be materially different from our estimated future results, performance or achievements expressed or implied by those forward-looking statements.Numerous factors could cause actual results to differ materially from those in the forward-looking statements, including without limitation, our ability to achieve increased market acceptance for our product offerings and penetrate new markets; consolidation in the healthcare industry; the existence of undetected errors or similar problems in our software products; our ability to identify and complete acquisitions, manage our growth and integrate acquisitions; our ability to compete successfully; potential liability for the use of incorrect or incomplete data; the length of the sales cycle for our healthcare software solutions; interruption of our operations due to outside sources; our dependence on key customers; maintaining our intellectual property rights and litigation involving intellectual property rights; our ability to obtain, use or successfully integrate third-party licensed technology; compliance with existing laws, regulations and industry initiatives and future change in laws or regulations in the healthcare industry; breach of our security by third parties; our dependence on the expertise of our key personnel; our access to sufficient capital to fund our future requirements; and potential write-offs of goodwill or other intangible assets.This list is not exhaustive of the factors that may affect any of our forward-looking statements.  Other factors that should be considered are discussed from time to time in SXC’s filings with the U.S. Securities and Exchange Commission, including the risks and uncertainties discussed under that captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2008 Annual Report on Form 10-K and subsequent Form 10-Qs, which are available at www.sec.gov.  Investors are cautioned not to put undue reliance on forward-looking statements.  All subsequent written and oral forward-looking statements attributable to SXC or persons acting on our behalf are expressly qualified in their entirety by this notice.  We disclaim any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Certain of the assumptions made in preparing forward-looking information and management’s expectations include: maintenance of our existing customers and contracts, our ability to market our products successfully to anticipated customers, the impact of increasing competition, the growth of prescription drug utilization rates at predicted levels, the retention of our key personnel, our customers continuing to process transactions at historical levels, that our systems will not be interrupted for any significant period of time, that our products will perform free of major errors, our ability to obtain financing on acceptable terms and that there will be no significant changes in the regulation of our business.

For more information, please contact:

Jeff Park	Dave Mason	Susan Noonan
Chief Financial Officer	Investor Relations - Canada	Investor Relations - U.S.
SXC Health Solutions, Inc.	The Equicom Group Inc.	The SAN Group, LLC
Tel: (630) 577-3100	(416) 815-0700 ext. 237	(212) 966-3650
investors@sxc.com	dmason@equicomgroup.com	susan@sanoonan.com

7

SXC HEALTH SOLUTIONS CORP.

Consolidated Balance Sheets

(in thousands, except share data)

	September 30,			December 31,
	2009			2008
	(unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	319,522		$	67,715
Restricted cash		12,433			12,498
Accounts receivable, net of allowance for doubtful accounts of $3,319 (2008 - $3,570)		90,083			80,531
Rebates receivable		20,577			29,586
Unbilled revenue		-			73
Prepaid expenses and other assets		4,718			4,382
Inventory		7,023			6,689
Income tax recoverable		-			1,459
Deferred income taxes		9,919			10,219
Total current assets		464,275			213,152
Property and equipment, net of accumulated depreciation of $25,388 (2008 - $19,449)		19,543			20,756
Goodwill		141,785			143,751
Other intangible assets, net of accumulated amortization of  $21,585 (2008 - $14,099)		39,820			46,406
Deferred financing charges		1,154			1,481
Deferred income taxes		1,846			1,323
Other assets		1,293			1,474
Total assets	$	669,716		$	428,343
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable	$	5,920		$	8,302
Customer deposits		12,553			11,875
Salaries and wages payable		13,184			15,681
Accrued liabilities		27,709			32,039
Pharmacy benefit management rebates payable		43,830			36,326
Pharmacy benefit claim payments payable		51,808			51,406
Deferred revenue		8,430			7,978
Current portion of long-term debt		4,800			3,720
Total current liabilities		168,234			167,327
Long-term debt, less current installments		40,320			43,920
Deferred income taxes		13,032			15,060
Deferred lease inducements		2,867			3,217
Deferred rent		1,327			1,461
Other liabilities		2,929			3,195
Total liabilities		228,709			234,180
Shareholders' equity
Common shares: no par value, unlimited shares authorized; 29,979,169 shares issued and outstanding at September 30, 2009  (2008 - 24,103,032 shares)		360,131			146,988
Additional paid-in capital		14,661			11,854
Retained earnings		66,619			35,751
Accumulated other comprehensive loss		(404	)		(430	)
Total shareholders' equity		441,007			194,163
Total liabilities and shareholders' equity	$	669,716		$	428,343

8

SXC HEALTH SOLUTIONS CORP.

Consolidated Statements of Operations

(in thousands, except per share data)

	Three months ended September 30,						Nine months ended September 30,
	2009			2008			2009			2008
	(unaudited)						(unaudited)
Revenue:
PBM	$	357,473		$	297,178		$	919,158		$	502,038
HCIT:
Transaction processing		16,461			11,631			45,852			38,167
Maintenance		4,733			3,998			13,684			12,338
Professional services		3,187			3,836			10,630			10,693
System sales		1,675			1,458			5,994			6,937
Total revenue		383,529			318,101			995,318			570,173
Cost of revenue:
PBM		321,234			272,654			819,608			460,700
HCIT		14,615			10,561			41,634			31,267
Total cost of revenue		335,849			283,215			861,242			491,967
Gross profit		47,680			34,886			134,076			78,206
Expenses:
Product development costs		2,833			2,486			9,024			7,425
Selling, general and administrative		22,153			21,863			64,857			47,291
Depreciation of property and equipment		1,467			1,222			4,354			3,416
Amortization of intangible assets		2,238			3,449			7,478			6,277
		28,691			29,020			85,713			64,409
Operating income		18,989			5,866			48,363			13,797
Interest income		(101	)		(508	)		(572	)		(2,209	)
Interest expense		1,088			1,609			3,248			2,407
Net interest expense		987			1,101			2,676			198
Other income, net		(20	)		(50	)		(62	)		(15	)
Income before income taxes		18,022			4,815			45,749			13,614
Income tax expense (benefit):
Current		9,215			3,356			15,818			5,335
Deferred		(2,402	)		(2,080	)		(937	)		(1,884	)
		6,813			1,276			14,881			3,451
Net income	$	11,209		$	3,539		$	30,868		$	10,163
Earnings per share:
Basic	$	0.45		$	0.15		$	1.25		$	0.45
Diluted	$	0.43		$	0.15		$	1.22		$	0.44
Weighted average number of shares used in computing earnings per share:
Basic		25,111,763			23,891,438			24,651,293			22,616,694
Diluted		26,109,202			24,346,740			25,318,349			23,034,651

9

SXC HEALTH SOLUTIONS CORP.

Consolidated Statements of Cash Flows

(in thousands)

	Three months ended						Nine months ended
	September 30,						September 30,
	2009			2008			2009			2008
	(unaudited)						(unaudited)
Cash flows from operating activities:
Net income	$	11,209		$	3,539		$	30,868		$	10,163
Items not involving cash:
Stock-based compensation		1,046			902			2,477			3,006
Depreciation of property and equipment		2,037			1,669			5,981			4,715
Amortization of intangible assets		2,239			3,449			7,478			6,277
Deferred lease inducements and rent		(115	)		(99	)		(484	)		(206	)
Deferred income taxes		(2,402	)		(2,080	)		(937	)		(1,884	)
Tax benefit on option exercises		(1,341	)		(719	)		(3,447	)		(799	)
Gain on foreign exchange		(24	)		(7	)		(50	)		(14	)
Changes in operating assets and liabilities, net of effects from acquisition:
Accounts receivable		(9,070	)		(4,970	)		(9,444	)		7,858
Rebates receivable		1,935			1,864			9,009			3,017
Restricted cash		1,702			(335	)		65			(4,660	)
Unbilled revenue		-			2			73			103
Prepaid expenses		862			(407	)		(302	)		915
Inventory		(915	)		93			(318	)		(171	)
Income tax recoverable		2,967			1,264			5,205			1,618
Accounts payable		(2,466	)		(768	)		(2,382	)		496
Accrued liabilities		2,441			1,211			(3,575	)		(4,452	)
Pharmacy benefit claim payments payable		9,868			2,585			402			1,049
Pharmacy benefit management rebates payable		(2,026	)		(2,632	)		7,504			(5,080	)
Deferred revenue		(63	)		(139	)		409			(393	)
Customer deposits		(94	)		(1,172	)		678			(1,070	)
Other		122			20			383			111
Net cash provided by operating activities		17,912			3,270			49,593			20,599
Cash flows from investing activities:
Purchases of property and equipment		(865	)		(2,556	)		(6,611	)		(5,970	)
Lease inducements received		-			-			-			373
Acquisitions, net of cash acquired		-			(892	)		(2,176	)		(102,562	)
Net cash used in investing activities		(865	)		(3,448	)		(8,787	)		(108,159	)
Cash flows from financing activities:
Issuance of long-term debt		-			-			-			48,000
Proceeds from public offering, net of issuance costs		204,107			-			204,107			-
Payment of financing costs		-			-			-			(1,792	)
Repayment of long-term debt		(1,200	)		(120	)		(2,520	)		(240	)
Proceeds from exercise of options		1,569			1,107			5,917			1,440
Tax benefit on option exercises		1,341			719			3,447			799
Net cash provided by financing activities		205,817			1,706			210,951			48,207
Effect of foreign exchange on cash balances		24			7			50			14
Increase (decrease) in cash and cash equivalents		222,888			1,535			251,807			(39,339	)
Cash and cash equivalents, beginning of period		96,634			50,055			67,715			90,929
Cash and cash equivalents, end of period	$	319,522		$	51,590		$	319,522		$	51,590

10